Compare Barrick Gold Corp (B) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Barrick Gold Corp vs Pfizer Inc — how do they compare? Barrick Gold Corp trades at $41.12 (market cap $65.92B), while Pfizer Inc trades at $26.27 (market cap $151.73B). The key difference: Pfizer Inc is far larger — about 2.3× Barrick Gold Corp's market cap, and Pfizer Inc pays the higher dividend (6.46%). Which is the better fit depends on your goals.
| B | PFE | |
|---|---|---|
Market Cap | $65.92B | $151.73B |
Sector | Basic Materials | Health |
52-Week High | $52.97 | $28.56 |
52-Week Low | $23.50 | $23.60 |
Enterprise Value | $64.67B | $203.22B |
Dividend Yield | 1.74% | 6.46% |
Volume | — | 29,869,932 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Barrick Mining (B) trades at $40.91, down 6.36% today, but maintains strong fundamentals with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $40 and resistance at $42, while recent developments include a $1.95 billion settlement with Newmont and plans for a North American gold IPO. Revenue growth accelerated to $17.0 billion in 2025 with net income reaching $5.0 billion, supported by a 31.6% net margin.
The outlook remains positive with 66.7% analyst buy ratings and a $49.83 consensus price target representing 22% upside. Key risks include gold price volatility and execution of the planned IPO, but strong cash flow generation and debt reduction provide stability for continued shareholder returns through dividends and potential buybacks.
Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.
The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Barrick Gold Corp
Barrick Gold Corp is one of the world's largest gold producers, operating mines in North America, South America, Australia, and Africa. The company segments consist of nine gold mines namely Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, and Bulyanhulu. It generates maximum revenue from the Carlin mine segment. Geographically, it derives a majority of revenue from the United States.
Read more on B →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
